Clinical Trials Logo

Clinical Trial Summary

Neonatal asphyxia per partum can be complicated by severe neurologic sequelae and can lead to neonatal death. Of the 0.2% of live births to cerebral palsy, 10 to 28% would be secondary to neonatal acidosis. Only metabolic acidosis plays a neurotoxic role, explaining the recent interest of Racinet et al. in the development of a new biochemical marker, more specific than pH or base deficit, of neonatal asphyxia per partum at risk of anoxo-ischemic encephalopathy. This eucapnic neonatal pH raises the hope of a biochemical marker of situations at risk of poor prognosis, with high diagnostic value, prognostic and forensic.

Our hypothesis is that eucapnic pH is more efficient than cord blood arterial pH and base deficit in the prediction of adverse neurologic outcomes.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03866876
Study type Observational
Source Hospices Civils de Lyon
Contact Muriel DORET, Prof.
Phone 4 27 85 51 70
Email muriel.doret-dion@chu-lyon.fr
Status Recruiting
Phase
Start date September 1, 2018
Completion date April 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04070131 - Horse Assisted Rehabilitation Postoncologic Treatment in Children and Adolescents: Physical and Psychological Effects N/A
Completed NCT04418609 - Neuro-COVID-19: Neurological Complications of COVID-19
Completed NCT06068673 - The Potential Impact of Clindamycin on Neurosurgery Patients. N/A
Not yet recruiting NCT04158024 - Erector Spinae Plane Block in Congenital Heart Disease Patients N/A
Completed NCT04188717 - Incidence, Risk Factors, Predictors and Survival for Neurological Complications After Liver Transplantation
Completed NCT04387513 - Impact of Early Cardiac Surgery in Severe Left Endocarditis With Neurological Complications: a Retrospective Study